

Genes and Common Diseases

Genes and common diseases presents an up-to-date view of the role of genetics in modern medicine, reflecting the strengths and limitations of a genetic perspective.

The current shift in emphasis from the study of rare single gene disorders to common diseases brings genetics into every aspect of modern medicine, from infectious diseases to therapeutics. However, it is unclear whether this increasingly genetic focus will prove useful in the face of major environmental influences in many common diseases.

The book takes a hard and self-critical look at what can and cannot be achieved using a genetic approach and what is known about genetic and environmental mechanisms in a variety of common diseases. It seeks to clarify the goals of human genetic research by providing state-of-the art insights into known molecular mechanisms underlying common disease processes while at the same time providing a realistic overview of the expected genetic and psychological complexity.

Alan Wright is a Programme Leader at the MRC Human Genetics Unit in Edinburgh.

Nicholas Hastie is Director of the MRC Human Genetics Unit in Edinburgh.



Genes and Common Diseases

Alan Wright

Nicholas Hastie

Foreword by David J. Weatherall





CAMBRIDGE UNIVERSITY PRESS

Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo

Cambridge University Press

The Edinburgh Building, Cambridge CB2 2RU, UK

Published in the United States of America by Cambridge University Press, New York

www.cambridge.org

Information on in this title: www.cambridge.org/9780521833394

© Cambridge University Press 2007

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2007

Printed in the United Kingdom at the University Press, Cambridge

A catalog record for this publication is available from the British Library

Library of Congress Cataloging in Publication data

Wright, Alan F., MRC.

Genes and common diseases / Alan Wright and Nicholas Hastie.

p.; cm.

Includes bibliographical references and index.

ISBN-13: 978-0-521-83339-4 (hardback)

ISBN-10: 0-521-83339-6 (hardback)

ISBN-13: 978-0-521-54100-8 (pbk.)

ISBN-10: 0-521-54100-X (pbk.)

1. Medical genetics. I. Hastie, Nicholas. II. Title.

[DNLM: 1. Genetic Predisposition to Disease. QZ 50 W947g 2007]

RB155.W75 2007

616'.042-dc22

2006102406

ISBN-13 978-0-521-83339-4 hardback ISBN-10 0-521-83339-6 hardback ISBN-13 978-0-521-54100-8 paperback

ISBN-10 0-521-54100-X paperback

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.



Contents

List Fore	<i>page</i> vii xiii	
Sect	tion 1: Introductory Principles	
1	Genes and their expression Dirk-Jan Kleinjan	3
2	Epigenetic modification of chromatin Donncha Dunican, Sari Pennings and Richard Meehan	20
3	Population genetics and disease Donald F. Conrad and Jonathan K. Pritchard	44
4	Mapping common disease genes Naomi R. Wray and Peter M. Visscher	59
5	Population diversity, genomes and disease Gianpiero L. Cavalleri and David B. Goldstei	80 n
6	Study design in mapping complex disease traits Harry Campbell and Igor Rudan	92
7	Diseases of protein misfolding Christopher M. Dobson	113
8	Aging and disease Thomas T. Perls	132
9	The MHC paradigm: genetic variation and complex disease Adrian P. Kelly and John Trowsdale	142



vi **Contents**

10	Lessons from single gene disorders Nicholas D. Hastie	152	23	Type 2 diabetes mellitus Mark I. McCarthy	344
11	Environment and disease A. J. McMichael and K. B. G. Dear	164	24	Genetics of coronary heart disease Rossi Naoumova, Stuart A. Cook, Paul Cook and Timothy J. Aitman	359
12	Contemporary ethico-legal issues in genetics Renate Gertz, Shawn Harmon and Geoffrey Pradella	176	25	Genetics of hypertension B. Keavney and M. Lathrop	377
			26	Obstructive pulmonary disease Bipen D. Patel and David A. Lomas	391
Section 2: Common Medical Disorders			27	Skeletal disorders Robert A. Colbert	406
13	Developmental disorders Stephen P. Robertson and Andrew O. M. Wilkie	201	28	The genetics of common skin diseases Jonathan Rees	427
14	Genes, environment and cancer D. Timothy Bishop	213	29	Molecular genetics of Alzheimer's disease and other adult-onset	
15	The polygenic basis of breast cancer Paul D. P. Pharoah and Bruce A. J. Ponder	224		dementias P. H. St George-Hyslop	
16	TP53: A master gene in normal and tumor suppression Pierre Hainaut	233	30	Major psychiatric disorders in adult life Amanda Elkin, Sridevi Kalidindi,	454
17	Genetics of colorectal cancer Susan M. Farrington and Malcolm G. Dunlop	245	31	Kopal Tandon and Peter McGuffin Speech and language disorders	469
18	Genetics of autoimmune disease	268	31	Gabrielle Barnby and Anthony J. Monaco	
19	John I. Bell and Lars Fugger Susceptibility to infectious diseases	277	32	Common forms of visual handicap Alan Wright	488
19	Andrew J. Walley and Adrian V. S. Hill	33	33	Genetic and environmental influences	505
20	Inflammatory bowel diseases Jean-Pierre Hugot	302		on hearing impairment Karen P. Steel	
21	Genetic anemias W. G. Wood and D. R. Higgs	316	34	Pharmacogenomics: clinical applications Gillian Smith, Mark Chamberlain and	516
22	Genetics of chronic disease: obesity I. Sadaf Farooqi and Stephen O'Rahilly	328		C. Roland Wolf	
				ex	529



Contributors

Adrian V.S. Hill

Human Genetics University of Oxford Wellcome Trust Centre for Human Genetics Oxford, UK

Adrian P. Kelly

Immunology Division Department of Pathology Cambridge, UK

A. J. McMichael

National Centre for Epidemiology and Population Health The Australian National University Canberra, Australia

Alan Wright

MRC Human Genetics Unit Western General Hospital Edinburgh, UK

Amanda Elkin

Neurogenetics Group Wellcome Trust Centre for Human Genetics Oxford, UK

۷ij

viii List of Contributors

Andrew J. Walley

Complex Human Genetics Imperial College London Section of Genomic Medicine Hammersmith Hospital London, UK

Andrew O.M. Wilkie

Weatherall Institute of Molecular Medicine The John Radcliffe Hospital Oxford University Oxford, UK

Anthony Monaco

Neurogenetics Group Wellcome Trust Centre for Human Genetics Oxford, UK

B. Keavney

Institute of Human Genetics University of Newcastle Newcastle, UK

Bipen D. Patel

Department of Public Health and Primary Care Institute of Public Health Cambridge University Cambridge, UK

Bruce A. J. Ponder

Cancer Research UK Human Cancer Genetics Group Department of Oncology Strangeways Research Laboratory Cambridge, UK

C. Roland Wolf

CR-UK Molecular Pharmacology Unit Ninewells Hospital & Medical School Dundee, UK

Christopher M. Dobson

Department of Chemistry University of Cambridge Cambridge, UK

David B. Goldstein

Department of Biology (Galton Lab) University College London London, UK

David A. Lomas

Respiratory Medicine Unit Department of Medicine University of Cambridge Cambridge Institute for Medical Research Cambridge, UK

Dirk-Jan Kleinjan

MRC Human Genetics Unit Western General Hospital Edinburgh, UK

Donald F. Conrad

Department of Human Genetics The University of Chicago Chicago IL USA

Donncha Dunican

MRC Human Genetics Unit Medical Research Council Western General Hospital Edingburgh, UK

D. R. Higgs

MRC Molecular Haematology Unit Weatherall Institute of Molecular Medicine University of Oxford John Radcliffe Hospital Oxford, UK

List of Contributors

ix

D. Timothy Bishop

Cancer Research UK Clinical Centre St James University Hospital University of Leeds Leeds, UK

Gabrielle Barnby

Neurogenetics Group Wellcome Trust Centre for Human Genetics Oxford, UK

Geoffrey Pradella

AHRC Research Centre for Studies in Intellectual Property and Technology Law University of Edinburgh Edinburgh, UK

Gianpiero L. Cavalleri

Department of Biology (Galton Lab) University College London London, UK

Gillian Smith

CR-UK Molecular Pharmacology Unit Ninewells Hospital & Medical School Dundee, UK

Harry Campbell

Department of Public Health Sciences University of Edinburgh Edinburgh, UK

I. Sadaf Faroogi

CIMR Wellcome Trust/MRC Building Addenbrookes' Hospital Cambridge, UK

Igor Rudan

School of Public Health Andrija Stampar University of Zagreb Zagreb, Croatia

Jean-Pierre Hugot

Department of Paediatric Gastroenterology INSERM Hopital Robert Debré Paris, France

John I. Bell

The Churchill Hospital University of Oxford Headington Oxford, UK

John Trowsdale

Immunology Division Department of Pathology Cambridge, UK

Jonathan K. Pritchard

Department of Human Genetics The University of Chicago Chicago IL USA

Jonathan Rees

Department of Dermatology University of Edinburgh Edinburgh, UK

Karen P. Steel

Wellcome Trust Sanger Institute Cambridge, UK

K. B. G. Dear

National Centre for Epidemiology and Population Health The Australian National University Canberra, Australia

Kopal Tandon

Neurogenetics Group Wellcome Trust Centre for Human Genetics Oxford, UK

x List of Contributors

Lars Fugger

The Churchill Hospital University of Oxford Headington Oxford, UK

Malcolm G. Dunlop

MRC Human Genetics Unit Western General Hospital Edinburgh, UK

Mark Chamberlain

CR-UK Molecular Pharmacology Unit Ninewells Hospital & Medical School Dundee, UK

M. Lathrop

Centre National de Genotypage France

Mark I. McCarthy

Oxford Centre for Diabetes, Endocrinology & Metabolism Churchill Hospital Site Headington Oxford, UK

Naomi R. Wray

Queensland Institute of Medical Research PO Royal Brisbane Hospital Brisbane, Australia

Nicholas D. Hastie

MRC Human Genetics Unit Western General Hospital Edinburgh, UK

Paul Cook

Division of Clinical Sciences Imperial College London, UK

Paul D. P. Pharoah

Cancer Research UK Human Cancer Genetics Group Department of Oncology Strangeways Research Laboratory Worts Causeway Cambridge, UK

Peter H. St George-Hyslop

Department of Medicine Division of Neurology The Toronto Hospital University of Toronto Toronto, Canada

Peter McGuffin

MRC Social, Genetic and Developmental Psychiatry Centre Institute of Psychiatry King's College London, UK

Peter M. Visscher

Queensland Institute of Medical Research PO Royal Brisbane Hospital Brisbane, Australia

Pierre Hainaut

International Agency for Research on Cancer Lyon, France

Renate Gertz

Generation Scotland
AHRC Research Centre for Studies in
Intellectual Property
and Technology Law
University of Edinburgh
Edinburgh, UK

Richard Meehan

MRC Human Genetics Unit Western General Hospital Edinburgh, UK



List of Contributors

χi

Robert A. Colbert

William S Rowe Division of Rheumatology Department of Paediatrics Cincinnati Children's Hospital Medica Center and The University of Cincinnati Cincinnati, USA

Rossi Naoumova

Division of Clinical Sciences Imperial College London, UK

Sari Pennings

Molecular Physiology University of Edinburgh Edinburgh, UK

Shawn Harmon

INNOGEN

ESRC Centre for Social and Economic Research on Innovation in Genomics University of Edinburgh, UK

Sridevi Kalidindi

Neurogenetics Group Wellcome Trust Centre for Human Genetics Oxford, UK

Stephen O'Rahilly

CIMR Wellcome Trust/MRC Building Addenbrookes' Hospital Cambridge, UK

Stephen P. Robertson

Department of Paediatrics and Child Health Dunedin School of Medicine Dunedin, New Zealand

Stuart A. Cook

Division of Clinical Sciences Imperial College London, UK

Susan M. Farrington

Colon Cancer Genetics Group Department of Surgery University of Edinburgh Edinburgh, UK

Thomas T. Perls

Boston University Medical Center Boston MA USA

Timothy J. Aitman

Division of Clinical Sciences Imperial College London, UK

W.G. Wood

MRC Molecular Haematology Unit Weatherall Institute of Molecular Medicine University of Oxford John Radcliffe Hospital Oxford, UK



Foreword

The announcement of the partial completion of the Human Genome Project was accompanied by expansive claims about the impact that this remarkable achievement will have on medical practice in the near future. The media and even some of the scientific community suggested that, within the next 20 years, many of our major killers, at least those of the rich countries, will disappear. What remains of day-to-day clinical practice will be individualized, based on a knowledge of a patient's particular genetic make-up, and survival beyond 100 years will be commonplace. Indeed, the hyperbole continues unabated; as I write a British newspaper announces that, based on the results of manipulating genes in small animals, future generations of humans can look forward to lifespans of 200 years.

This news comes as something of a surprise to the majority of practicing doctors. The older generation had been brought up on the belief that most diseases are environmental in origin and that those that are not, vascular disease and cancer for example, can be lumped together as "degenerative", that is the natural consequence of increasing age. More recent generations, who know something about the interactions between the environment and vascular pathology and are aware that cancer is the result of the acquisition of mutations of oncogenes, still believe that environmental risk factors are the major cause of illness; if we run six miles before breakfast, do not smoke, imbibe only homeopathic doses of alcohol, and survive on the same diets as our

XIII



xiv Foreword

hunter-gatherer forebears, we will grow old gracefully and live to a ripe old age. Against this background it is not surprising that today's doctors were astonished to hear that a knowledge of our genetic make-up will transform their practice almost overnight.

The rather exaggerated claims for the benefits of genomics for clinical practice stem from the notion that, since twin studies have shown that there is a variable genetic component to most common diseases, the definition of the different susceptibility genes involved will provide a great deal of information about their pathogenesis and, at the same time, offer the pharmaceutical industry many new targets for their management. An even more exciting prospect is that it may become possible to identify members of the community whose genetic make-up renders them more or less prone to noxious environmental agents, hence allowing public health measures to be focused on subgroups of populations. And if this is not enough, it is also claimed that a knowledge of the relationship between drug metabolism and genetic diversity will revolutionize clinical practice; information about every patient's genome will be available to their family practitioners, who will then be able to adjust the dosage of their drugs in line with their genetic constitution.

Enough was known long before the completion of the Genome Project to suggest that the timescale of this rosy view of genomics and health is based more on hope than reality. For example, it was already clear that the remarkable phenotypic diversity of single gene disorders, that is those whose inheritance follows a straightforward Mendelian pattern, is based on layer upon layer of complexity, reflecting multiple modifier genes and complex interactions with the environment. Even after the fruits of the Genome Project became available, and although there were a few successes, genome-wide searches for the genes involved in modifying an individual's susceptibility to common diseases often gave ambiguous results. Similarly, early hopes that sequence data obtained from pathogen genomes, or those of their vectors, would provide targets for drug or vaccine development have been slow to come to fruition. And while there have been a few therapeutic successes in the cancer field — the development of an agent directed at the abnormal product of an oncogene in a common form of human leukemia for example — an increasing understanding of the complexity of neoplastic transformation at the molecular level has emphasized the problems of reversing this process.

In retrospect, none of these apparent setbacks should have surprised us. After all, it seems likely that most common diseases, except monogenic disorders, reflect a complex interplay between multiple and variable environmental factors and the individual responses of patients which are fine-tuned by the action of many different genes, at least some of which may have very small phenotypic effects. Furthermore, many of the refractory illnesses, particularly those of the rich countries, occur in middle or old age and hence the ill-understood biology of aging adds yet another level of complexity to their pathogenesis. Looked at in this way, it was always unlikely that there would be any quick answers to the control of our current killers.

Because the era of molecular medicine is already perceived as a time of unfulfilled promises, in no small part because of the hype with which it was heralded, the field is being viewed with a certain amount of scepticism by both the medical world and the community at large. Hence, this book, which takes a hard-headed look at the potential of the role of genetics for the future of medical practice, arrives at a particularly opportune time. The editors have amassed an excellent team of authors, all of whom are leaders in their particular fields and, even more importantly, have worked in them long enough to be able to place their potential medical roles into genuine perspective. Furthermore, by presenting their research in the kind of language which will make their findings available to practising doctors, they have performed an invaluable service by interpreting the complexities of genomic medicine for their clinical colleagues.



Foreword

X۷

The truth is that we are just at the beginning of the exploration of disease at the molecular level and no-one knows where it will lead us in our search for better ways of controlling and treating common illness, either in the developing or developed countries. In effect, the position is very similar to that during the first dawnings of microbiology in the second half of the nineteenth century. In March 1882, Robert Koch announced the discovery of the organism that causes tuberculosis. This news caused enormous excitement throughout the world; an editorial writer of the London Times newspaper assured his readers that this discovery would lead immediately to the treatment of tuberculosis, yet 62 frustrating years were to elapse before Selman Waksman's announcement of the development of streptomycin. There is often a long period between major discoveries in the research laboratory and their application in the clinic; genomics is unlikely to be an exception.

Those who read this excellent book, and I hope that there will be many, should be left in no doubt that the genetic approach to medical

research and practice offers us the genuine possibility of understanding the mechanisms that underlie many of the common diseases of the richer countries, and, at the same time, provides a completely new approach to attacking the major infectious diseases which are decimating many of the populations of the developing countries. Since we have no way of knowing the extent to which the application of our limited knowledge of the environmental causes of these diseases to their control will be successful, it is vital that we make full use of what genomics has

We are only witnessing the uncertain beginnings of what is sure to be an extremely exciting phase in the development of the medical sciences; scientists should constantly remind themselves and the general public that this is the case, an approach which is extremely well exemplified by the work of the editors and authors of this fine book. I wish them and their publisher every success in this new venture.

D. J. Weatherall Oxford